Press

Love Pharma Updates Microdoz Proposed Acquisition with Global Leader in Psychedelic Research

Mar 4 • 4 min read

LOVE Pharma Co. (CSE: LUV | FSE: G1Q0), the Company is pleased to announce updated details on the proposed Microdoz Therapy acquisition (originally announced in a press release on November 23, 2021), whereby Microdoz has engaged exclusively with researchers at Johns Hopkins University, the top psychedelic center in the World, located in the eastern United States,…

Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care

Mar 3 • 3 min read

Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP), a global leader in the development and delivery of psychedelic-assisted psychotherapy, today announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health’s ketamine assisted therapy, while Field Trip…

Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights

Mar 2 • 3 min read

Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and six months ended December 31, 2021. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. “We’re pleased to report record high…

HAVN Life Sciences Health Products Listed On Amazon

Feb 28 • 3 min read

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF), a biotechnology company developing natural health products and innovative therapies to support brain health and cognitive function, announced that its portfolio of natural health products is now available through Amazon.com. The ecommerce giant carries the full line of HAVN Life’s natural health products launched last June, and ships to…

HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research

Feb 25 • 5 min read

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is pleased to announce it has successfully secured a purchase order for naturally derived psilocybin from their Canadian supply partner, Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) (FSE: 31R) (“Revive”)…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435